130 Efficacy and Safety of Obefazimod in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Two, Phase 3, Randomised, Double-Blind, Placebo-Controlled, 8-Week Induction Trials (ABTECT-1 and 2)
Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Séverine Vermeire(KU Leuven), Marla C. Dubinsky(Icahn School of Medicine at Mount Sinai), Ursula Seidler(Medizinische Hochschule Hannover), Parambir S. Dulai(Northwestern Medicine), Xavier Treton(Clinique Hartmann), Britta Siegmund(Humboldt-Universität zu Berlin), Raja Atreya(Friedrich-Alexander-Universität Erlangen-Nürnberg), Tadakazu Hisamatsu(Kyorin University), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Herbert Tilg(Innsbruck Medical University), Silvio Danese(IRCCS Ospedale San Raffaele), David T. Rubin(University of California System), Christopher J. Rabbat(Abivax (France)), Fabio Cataldi(Abivax (France)), Alessandro Armuzzi, Doug Jacobstein(Abivax (France)), George Duvall, Filip Baert(AZ Delta)
Cited by 1
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k